• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Taiwan·Healthcare·6797.TWO
Share

Taiwan Advanced Nanotech Inc. Stocks

NT$ 11.1Last Updated 20.10.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

NT$ 10.20M

NT$ 11.1
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Taiwan Advanced Nanotech Inc. (TAN) specializes in the creation and manufacturing of products essential for isolating nucleic acids. The company's diverse range of offerings includes specialized reagent kits, which are utilized for extracting DNA and RNA from a wide array of biological specimens such as blood, cells, tissues, plants, bacteria, and viruses. TAN also supplies magnetic nanoparticles, specifically super-paramagnetic iron oxide and ultra-small super-paramagnetic iron oxide, designed for various molecular biology applications. Their product line extends to automated instruments for efficient genetic material extraction and crucial consumables like spin tips and deep well plates. These solutions are provided to public health agencies, diagnostic laboratories, hospitals, and other related clinical and research institutions. The company, established in 2004, operates out of Taoyuan, Taiwan.

Company Valuation

Fairly valued
4/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. Specifically, the stock is overpriced on P/FCF.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

20.10.2026 17:10

Netflix shares have fallen by a quarter since the start of the year. Should you buy them before the earnings report?

20.10.2026 16:50

Shares of biotech company Disc had their best day in four years. Its project has been given a second chance

20.10.2026 16:28

CoreWeave's stock continued to fall. Why does Barclays think the panic is overblown?

20.10.2026 15:25

Morning in New York: Earnings Reports Will Test the Sustainability of the AI Stock Rally

20.10.2026 15:24

Reuters identified a possible cause of the Revolut outage

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026